Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone + Interferon Alfacon-1 + Ribavirin in HCV GT1 Non-responders
NCT00207402Phase 4Completed
- Sponsor
- Brooke Army Medical Center
- Start
- Oct 2005
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rosiglitazone in hepatitis C (HCV) (2 arms), sponsored by Brooke Army Medical Center. Primary endpoint: Change in viral kinetics with improvement of insulin sensitivity at 104 days. Started Oct 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00207402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00207402.